Effect of MRA on Cardiovascular Disease in Patients With Hypertension and Hyperaldosteronemia

Other illness

• Known secondary cause of hypertension, including pheochromocytoma, primary aldosteronism (adrenal tumor \> 1cm), Cushing's syndrome, renal artery stenosis, renin tumor, connotation of aorta, etc.;
• History of ischemic or hemorrhagic stroke within the last 3 months (not lacunar infarction and transient ischemic attack \[TIA\]).
• History of Hospitalization for myocardial infarction or unstable angina, or coronary revascularization (PCI or CABG) within the last 3 months.
• History of aortic dissection/dissection aneurysm rupture.
• History of NYHA Grade III-IV heart failure or hospitalization Aggravated chronic heart failure upon admission within the last 3 months.
• A history of persistent atrial fibrillation, atrial flutter, or other severe arrhythmias on admission (including sinus delay, diseased sinus, high atrioventricular block, frequent ventricular morning, etc.).
• Patients with serious physical diseases such as malignant tumors and autoimmune diseases.
• Severe cognitive or mental impairment.
• Those who have contraindications or allergies to MRAs.

Lab values

• Severe liver disease or liver dysfunction: AST, ALT, or ALP \> 5ULN (5 times the upper limit of normal), or BIL \> 3ULN (3 times the upper limit of normal).
• End-stage renal disease (ESRD) on dialysis, or estimated glomerular filtration rate (eGFR) \<30 mL/min, or serum creatine \>2.5 mg/dl \[\>221 umol/L\];

Other

• SBP/DBP≥190/120mmHg, DBP\<60 mmHg;
• Pregnant and lactating women.
• Patients with hypoadrenocortical function.
• Participating in other clinical trials.

• Age: 18-75 years old;
• Blood pressure ≥140/90 mmHg, or have taken antihypertensive drugs;
• Plasma aldosterone concentration\> 12ng/ dL;
• Serum potassium \< 4.8mmol/L;
• Signed the written informed consent.